RIO-North America study
Jump to navigation
Jump to search
Introduction
Study characteristics:
Treatment:
- rimonabant 5 mg, 20 mg
- placebo
Results:
- 5 kg weight loss over 1 year (20 mg/day)
- non-adherence 40%, dropout 7%[1]
More general terms
References
- ↑ 1.0 1.1 Pi-Sunyer FX et al, RIO-North America Study Group Effect of rimonanbant, a cannabinoid-1 receptor blocker on weight and cardiometabolic risk factors in overweight or obese patients. RIO-Norht America: A randomized controlled trial. JAMA 2006; 295:761 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16478899
Simons-Morton DG et al, Obesity research - Limitations of methods, measurements, and medications. JAMA 2006; 295:826 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16478906